Search Results

Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, has received clearance to conduct a Phase I/II trial for its novel Huntington’s Disease gene therapy, BV-101, in France through its subsidiary BrainVectis.

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that the European Commission (EC) has granted orphan drug designation for AB-1003 (also known as LION-101)* for the treatment of limb-girdle muscular dystrophy (LGMD).

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.

BrainVectis will begin assessing a gene therapy for Huntington’s disease in France after receiving clearance from health authorities there to conduct a Phase I/II study.

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in Phase 1 / Phase 2 LION-CS101 clinical trial of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Michael Kranda has joined the company to lead its central nervous system (CNS) therapeutic sector and programs.

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman.